Smartee Launches Early Orthodontic Solutions for Children and Teens in Australia
SYDNEY, Sept. 2, 2025 /PRNewswire/ -- Smartee Denti-Technology, a global leader in innovative clear aligner solutions, has officially launched its clear aligner products for children and teenagers in Australia. The product lines include Smartee Kinder and Smartee Teen, are designed to address the unique orthodontic challenges of growing patients at different developmental stages. Dr. Gareth Ho (Left) and...
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment
SEOUL, South Korea, Sept. 3, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developing catheter-based intravascular ultrasound renal denervation (RDN) treatment that was acquired by Boston Scientific for...
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 "The FDA approvals of BILDYOS and BILPREVDA...
Lunit Selected as Exclusive AI Partner for Spain’s Valencian Community Breast Screening Program
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions have been selected as the exclusive AI tools for the breast cancer screening...
Desilo to Launch “HARVEST™,” Encrypted Data Collaboration Platform for Healthcare, in December
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform, HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical companies to collaborate on research without exposing sensitive patient data. HARVEST™ by Desilo lets healthcare...
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer’s disease and Dementia Data
Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for...
Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants
- The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees to be announced in August 2026- Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndromic PCR assays, instruments, and software- Program aims to...
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate...
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen, Denmark: EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients. NEW...
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as international standards amid projected global market growth to USD 6.3 billion by 3034 SKBS continues strategic R&D to enhance global vaccine competitiveness of its vaccine pipelines ...
